Using blood DNA to assess response after breast cancer chemotherapy
Part of Cancer, Skin clinical trials.
This study checks whether a blood test that looks for “tumor DNA” (circulating tumor DNA) can help evaluate how well neoadjuvant chemotherapy worked for breast cancer. It may help doctors better understand treatment response after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can participate as either a woman or a man.
- You had invasive breast cancer diagnosed by biopsy before starting chemotherapy.
- Your cancer was considered locally advanced (often not operable right away) or meets specific operable stage patterns, with no evidence of spread to distant organs at the initial diagnosis (M0).
- Before surgery, you received 6–8 cycles of neoadjuvant chemotherapy (pre-surgery chemo).
- After surgery, your pathology showed a non-complete response (not a complete disappearance of tumor in breast and lymph nodes, such as not only ypT0/is and ypN0).
- You can have blood/tissue procedures and follow the study plan, and you can sign consent (study requires French social security coverage).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a blood test for “circulating tumor DNA” (tiny pieces of cancer-related DNA in the blood). It may help doctors learn more about digestive, gynecologic, or breast cancers and how patients respond when treatment like chemotherapy or immunotherapy is needed.
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
This study looks for tiny bits of tumor DNA in your blood after surgery to see if it can help guide future treatment. It's for people who had surgery first (not chemotherapy before surgery) and have not seen the cancer spread.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial is studying tiny molecules in your blood (called microRNAs) to see if they can predict how well breast cancer responds to chemotherapy given before surgery. If you are starting neoadjuvant chemotherapy, this study may help personalize your treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.